(EFE) – The first Americans could start receiving the vaccine against COVID-19 on December 12, predicted this Sunday the main adviser of Operation “Warp Speed”, the White House team that tries to accelerate medical solutions to the pandemic.
Advisers to the US Food and Drug Administration (FDA), will meet on December 10 to decide whether to approve the vaccine developed by the pharmaceutical company Pfizer and its German partner BioNTech, who this Friday requested an emergency authorization for its preparation in the North American country.
If you are cleared that same day, the US government is “ready to begin distributing vaccines within 24 hours of approval”, assured the advisor of Operation “Warp Speed”, Moncef Slaoui, in an interview with the chain ABC News.
“We will have the (first) vaccines (distributed) one day after approval, and we hope that people can start to be immunized, I would say within 48 hours of approval, “that is, on December 12, Slaoui added.
If that happens, the expert calculated that the United States could return to the closest thing to a new normal. “Sometime in the month of May” 2021, when he estimated that 70% of the population will have received the vaccine and group immunity will have been achieved.
The first vaccines will be distributed in a proportional way to the population of each state, and those territories will be able to decide who will have priority to receive it, usually among the high-risk population and medical professionals, Slaoui explained.
The Trump administration has given few details on how you will meet the challenge of vaccinating America’s more than 330 million people, and he has not shared his plans with the team of president-elect, Joe Biden, who has warned that such lack of cooperation could cost lives in the country.
Slaoui’s schedule implies that the first vaccines could be run more than a month before Biden takes office, next January 20.
The vaccination effort will also have to address the distrust of many Americans toward the vaccine: only 58% of citizens are willing to have it administeredaccording to a poll released this week by Gallup.
Pfizer’s vaccine requires two doses given about three weeks apart, and has shown up to 95% efficacy in preliminary clinical trials, without major safety concerns.
The United States has another candidate who has also demonstrated the effectiveness of its vaccine, that of the Modern Pharmaceutical, which could request emergency authorization shortly and that, unlike Pfizer, does owe part of its success in the historically rapid development process of the preparation to the injection of funds from the US government.
The North American country is in the midst of a rebound in COVID-19 infections: has already exceeded 12 million cases of coronavirus and already has more than 255,000 deaths, more than any other country in the world.